These preliminary findings indicate that BDNF and its polymorphism may represent a potential biomarker for susceptibility and severity of CI in MS, as well as a possible therapeutic target of pharmacological interventions for neuropsychological dysfunction. The gene discussed is BDNF; the disease is myeloid sarcoma.